The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor
Overview
Authors
Affiliations
Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family involved in tumor-associated angiogenesis and melanoma invasion of the extra-cellular matrix (ECM) through activation of membrane VEGF receptor 1 (VEGFR-1). A soluble VEGFR-1 (sVEGFR-1) form is released in the ECM, where it sequesters proangiogenic factors and stimulates endothelial or tumor cell adhesion and chemotaxis through interaction with α5β1 integrin. The anti-VEGFR-1 monoclonal antibody (D16F7 mAb) inhibits VEGF-A or PlGF-mediated signal transduction without affecting ligand interaction, thus preserving sVEGFR-1 decoy function. The aim of this study was to investigate whether D16F7 mAb hampers melanoma spread by in vitro analysis of cell adhesion to sVEGFR-1, ECM invasion, transmigration through an endothelial cell monolayer and in vivo evaluation of tumor infiltrative potential in a syngeneic murine model. Results indicate that D16F7 mAb significantly inhibits melanoma adhesion to sVEGFR-1 and ECM invasion, as well as transmigration in response to PlGF. Moreover, treatment of melanoma-bearing mice with the anti-VEGFR-1 mAb not only inhibits tumor growth but also induces a significant reduction in bone infiltration associated with a decrease in PlGF-positive melanoma cells. Furthermore, D16F7 mAb reduces PlGF production by melanoma cells. Therefore, blockade of PLGF/VEGFR-1 signaling represents a suitable strategy to counteract the metastatic potential of melanoma.
Mico-Carnero M, Rojano-Alfonso C, Maroto-Serrat C, Cutrin J, Casillas-Ramirez A, Peralta C Front Cell Dev Biol. 2025; 12():1455258.
PMID: 39839674 PMC: 11747040. DOI: 10.3389/fcell.2024.1455258.
Prognostic Value of PlGF Upregulation in Prostate Cancer.
Scimeca M, Giacobbi E, Servadei F, Palumbo V, Palumbo C, Finazzi-Agro E Biomedicines. 2024; 12(10).
PMID: 39457506 PMC: 11505493. DOI: 10.3390/biomedicines12102194.
Angiogenesis Still Plays a Crucial Role in Human Melanoma Progression.
Cazzato G, Ingravallo G, Ribatti D Cancers (Basel). 2024; 16(10).
PMID: 38791873 PMC: 11120419. DOI: 10.3390/cancers16101794.
Programmed Cell Death Pathways in Cholangiocarcinoma: Opportunities for Targeted Therapy.
Scimeca M, Rovella V, Palumbo V, Scioli M, Bonfiglio R, Tor Centre Cancers (Basel). 2023; 15(14).
PMID: 37509299 PMC: 10377326. DOI: 10.3390/cancers15143638.
Rekowska A, Obuchowska K, Bartosik M, Kimber-Trojnar Z, Slodzinska M, Wierzchowska-Opoka M Cancers (Basel). 2023; 15(9).
PMID: 37174083 PMC: 10177254. DOI: 10.3390/cancers15092618.